Cal-Maine Foods, Inc. (CALM) Income Statement

The deceleration is strikingly orderly rather than cliff-like: sequential revenue of $922.6M, $769.5M, $667.0M, $552.6M and $539.6M across 2026 indicates a steady normalization of wholesale egg prices rather than a single demand shock. Because Cal-Maine's pricing is tied to the Urner Barry index, this trajectory appears to reflect the scarcity premium dissipating as industry flock capacity recovers, not a loss of volume share — a distinction investors should test against disclosure on dozen case sales. The contrast with Vital Farms' 25.3% revenue growth over the same window implies the decline is company- and commodity-specific rather than a category-wide retrenchment, which raises the question of whether the TTM revenue base of ~$2.91 billion is a cyclical trough or a new operating plateau.

A 0.1% gross margin on an industrial-scale operation is an extreme reading, and it warrants scrutiny of what sits inside COGS — feed inflation at the same time egg prices retreat, elevated per-unit labor and biosecurity costs, and any write-downs of biological assets or unplaced inventory during HPAI culls could all be embedded in the $539.2 million cost line. The margin trajectory — 50.5%, 48.2%, 37.3%, 33.7%, 27.0%, 17.9%, 6.2%, 0.1% — shows compression far outpacing the revenue decline in absolute terms, which suggests the spread between grain inputs and shell egg prices has inverted rather than merely narrowed. Management's historical claim that specialty eggs carry a structurally higher margin floor is not yet visible in the reported figures, and if conventional volume dominates the loss quarter, that mix shift may be further away than the strategic narrative implies.

Operating income has swung from $635.7 million at the 2025Q3 peak to an operating loss of $83.7 million, a move of over $700 million in two years, while SG&A has grown roughly 36% over the same horizon — meaning the overhead base was expanded into peak-cycle cash flows that have now receded. The result is that SG&A alone consumes roughly twenty times the trailing gross profit, a structural imbalance that will only reverse if either volume recovers or costs are meaningfully cut. Because R&D is reported at zero across all ten quarters, the expense discipline question sits entirely within SG&A, and the year-over-year uptick to $93.6 million in 2026Q4 suggests the organization was not downsized in anticipation of the downturn. Investors should watch whether SG&A is being actively reduced or whether the reported loss reflects a company still spending against a business model sized for peak pricing.

The 2025Q3-2026Q1 window appears to represent the maximum of the HPAI-driven scarcity cycle: revenue of $1.4 billion and $922.6 million produced operating margins of 44.8% and 27.0%, figures that are unlikely to recur unless supply-side disruption again constricts national flock availability. The lasting impact is a substantially higher cost and capital base — expanded facilities, cage-free conversion commitments and a larger SG&A line — that was financed at peak-cycle earnings and must now be carried against a far weaker spread. This matters because the inflection is not simply a revenue event but a capital-efficiency event: returns on the capacity added at the top of the cycle will be determined by whether pricing stabilizes at a level that clears the new cost structure.